دورية أكاديمية
أعرض في EDS

Effects of nucleo(s)tide analogs therapy on chronic hepatitis B as evaluated by hepatosplenic radionuclide angiography.

التفاصيل البيبلوغرافية
العنوان: Effects of nucleo(s)tide analogs therapy on chronic hepatitis B as evaluated by hepatosplenic radionuclide angiography.
المؤلفون: Wang L; State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China., Wu Z, Wang A, Jin X, Qiu Y
المصدر: Nuclear medicine communications [Nucl Med Commun] 2020 Apr; Vol. 41 (4), pp. 314-319.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8201017 Publication Model: Print Cited Medium: Internet ISSN: 1473-5628 (Electronic) Linking ISSN: 01433636 NLM ISO Abbreviation: Nucl Med Commun Subsets: MEDLINE
أسماء مطبوعة: Publication: London : Lippincott Williams & Wilkins
Original Publication: London : Chapman and Hall in association with the British Nuclear Medicine Society, c1980-
مواضيع طبية MeSH: Radionuclide Angiography*, Hepatitis B, Chronic/*diagnostic imaging , Hepatitis B, Chronic/*drug therapy , Nucleosides/*chemistry , Nucleosides/*therapeutic use , Nucleotides/*chemistry , Nucleotides/*therapeutic use, Adult ; Disease Progression ; Female ; Hepatitis B, Chronic/pathology ; Humans ; Male ; Retrospective Studies
مستخلص: Objectives: Hepatosplenic radionuclide angiography is a relatively noninvasive method for evaluating hepatic portal perfusion. We used hepatosplenic radionuclide angiography to assess the effects of nucleo(s)tide analogs therapy on patients with chronic hepatitis B (CHB).
Patients and Methods: A retrospective analysis was performed on patients who underwent hepatosplenic radionuclide angiography from January 2012 to May 2017 at the First Affiliated Hospital, College of Medicine, Zhejiang University. The correlations between the results of routine laboratory tests and hepatic perfusion index (HPI) were evaluated. The Wilcoxon signed-rank test and one-way ANOVA of repeated measures were used to compare the HPIs of patients who received nucleo(s)tide analogs therapy.
Results: There is a positive correlation between HPI and cholinesterase and serum albumin (ALB) and a negative correlation between HPI and aspartate aminotransferase-to-platelet ratio index and bilirubin (TBiL). An improvement in HPI was observed in patients with an initial HPI <61% after nucleo(s)tide analogs therapy.
Conclusions: Hepatosplenic radionuclide angiography can reflect the functional reserve of the liver and monitor liver fibrosis indirectly. It can also comprehensively assess the effects of antiviral therapy on patients with CHB, and antiviral therapy is critical for the treatment of hepatitis.
References: Liang P, Zu J, Yin J, Li H, Gao L, Cui F, et al. The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in china, 1992-2006: a mathematical model analysis. J Theor Biol. 2015; 386:115–121.
Wu JF, Chang MH. Natural history of chronic hepatitis B virus infection from infancy to adult life - the mechanism of inflammation triggering and long-term impacts. J Biomed Sci. 2015; 22:92.
Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014; 384:2053–2063.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013; 381:468–475.
Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017; 66:275–281.
Sonneveld MJ. Core inhibitor therapy for chronic hepatitis B. Lancet Gastroenterol Hepatol. 2019; pii:S2468–S1253.
Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018; 392:2313–2324.
Germani G, Hytiroglou P, Fotiadu A, Burroughs AK, Dhillon AP. Assessment of fibrosis and cirrhosis in liver biopsies: an update. Semin Liver Dis. 2011; 31:82–90.
Ragazzo TG, Paranagua-Vezozzo D, Lima FR, de Campos Mazo DF, Pessoa MG, Oliveira CP, et al. Accuracy of transient elastography-fibroscan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. Clinics (Sao Paulo). 2017; 72:516–525.
Zhu X, Wang LC, Chen EQ, Chen XB, Chen LY, Liu L, et al. Prospective evaluation of fibroscan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci. 2011; 56:2742–2749.
European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015; 63:237–264.
de Carvalho BT, Coutinho Domingues AL, de Almeida Lopes EP, Brandão SC. Increased hepatic arterial blood flow measured by hepatic perfusion index in hepatosplenic schistosomiasis: new concepts for an old disease. Dig Dis Sci. 2016; 61:2118–2126.
O’Connor MK, MacMathuna P, Keeling PW. Hepatic arterial and portal venous components of liver blood flow: a dynamic scintigraphic study. J Nucl Med. 1988; 29:466–472.
Buechter M, Thimm J, Baba HA, Bertram S, Willuweit K, Gerken G, et al. Liver maximum capacity: a novel test to accurately diagnose different stages of liver fibrosis. Digestion. 2018; 100:1–10.
Sarper R, Fajman WA, Rypins EB, Henderson JM, Tarcan YA, Galambos JT, Warren WD. A noninvasive method for measuring portal venous/total hepatic blood flow by hepatosplenic radionuclide angiography. Radiology. 1981; 141:179–184.
Rypins EB, Fajman W, Sarper R, Henderson JM, Kutner MH, Tarcan YA, et al. Radionuclide angiography of the liver and spleen. Noninvasive method for assessing the ratio of portal venous to total hepatic blood flow and portasystemic shunt patency. Am J Surg. 1981; 142:574–579.
Hou JL, Lai W; Chinese Society of Hepatology CMA, Chinese Society of Infectious Diseases CMA. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Zhonghua Gan Zang Bing Za Zhi. 2015; 23:888–905.
Lesi O, MacMahon B, Siegfried N, Abraham P, Aghokeng AF, Andrieux-Meyer I, et al. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. 2015, Geneva: WHO Guidelines Approved by the Guidelines Review Committee.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50:661–662.
Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6:531–561.
European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57:167–185.
Wong S, Huynh D, Zhang F, Nguyen NQ. Use of aspartate aminotransferase to platelet ratio to reduce the need for fibroscan in the evaluation of liver fibrosis. World J Hepatol. 2017; 9:791–796.
Lieber CS, Weiss DG, Paronetto F; Veterans Affairs Cooperative Study 391 Group. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res. 2008; 32:1031–1039.
Mendes LC, Ferreira PA, Miotto N, Zanaga L, Gonçales E, Lazarini MS, et al. Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C. Braz J Med Biol Res. 2016; 49:e5432.
Abdollahi M, Pouri A, Ghojazadeh M, Estakhri R, Somi M. Non-invasive serum fibrosis markers: study in chronic hepatitis. Bioimpacts. 2015; 5:17–23.
Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002; 97:2614–2618.
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38:518–526.
Ho SY, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, et al. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One. 2017; 12:e0180408.
Hu T, Yao L, Hu A, Jiang S, Ying H, Deng Q, et al. Nucleos(t)ide analogs improve long-term prognosis in patients with chronic hepatitis B-associated liver failure. Hepatol Res. 2017; 47:347–358.
McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009; 49:S45–S55.
Liang J, Tang YF, Wu FS, Deng X. Entecavir versus lamivudine for the treatment of chronic hepatitis B: a systematic review. Pharmazie. 2012; 67:883–890.
Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010; 52:886–893.
Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, et al. Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in asians with chronic hepatitis B. Dig Dis Sci. 2015; 60:260–268.
Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, et al. Long-term telbivudine treatment results in resolution of liver inflammation and fibrosis in patients with chronic hepatitis B. Adv Ther. 2015; 32:727–741.
Audsley J, Robson C, Aitchison S, Matthews GV, Iser D, Sasadeusz J, Lewin SR. Liver fibrosis regression measured by transient elastography in human immunodeficiency virus (HIV)-hepatitis B virus (HBV)-coinfected individuals on long-term HBV-active combination antiretroviral therapy. Open Forum Infect Dis. 2016; 3:ofw035.
المشرفين على المادة: 0 (Nucleosides)
0 (Nucleotides)
تواريخ الأحداث: Date Created: 20200116 Date Completed: 20210104 Latest Revision: 20210212
رمز التحديث: 20240628
DOI: 10.1097/MNM.0000000000001156
PMID: 31939901
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-5628
DOI:10.1097/MNM.0000000000001156